196 related articles for article (PubMed ID: 30953499)
1. Novel biomarkers distinguishing pancreatic head Cancer from distal cholangiocarcinoma based on proteomic analysis.
Takenami T; Maeda S; Karasawa H; Suzuki T; Furukawa T; Morikawa T; Takadate T; Hayashi H; Nakagawa K; Motoi F; Naitoh T; Unno M
BMC Cancer; 2019 Apr; 19(1):318. PubMed ID: 30953499
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical Markers Distinguishing Cholangiocellular Carcinoma (CCC) from Pancreatic Ductal Adenocarcinoma (PDAC) Discovered by Proteomic Analysis of Microdissected Cells.
Padden J; Ahrens M; Kälsch J; Bertram S; Megger DA; Bracht T; Eisenacher M; Kocabayoglu P; Meyer HE; Sipos B; Baba HA; Sitek B
Mol Cell Proteomics; 2016 Mar; 15(3):1072-82. PubMed ID: 26644413
[TBL] [Abstract][Full Text] [Related]
3. Urine proteomics study reveals potential biomarkers for the differential diagnosis of cholangiocarcinoma and periductal fibrosis.
Duangkumpha K; Stoll T; Phetcharaburanin J; Yongvanit P; Thanan R; Techasen A; Namwat N; Khuntikeo N; Chamadol N; Roytrakul S; Mulvenna J; Mohamed A; Shah AK; Hill MM; Loilome W
PLoS One; 2019; 14(8):e0221024. PubMed ID: 31425520
[TBL] [Abstract][Full Text] [Related]
4. Annexin A10 optimally differentiates between intrahepatic cholangiocarcinoma and hepatic metastases of pancreatic ductal adenocarcinoma: a comparative study of immunohistochemical markers and panels.
Kälsch J; Padden J; Bertram S; Pott LL; Reis H; Westerwick D; Schaefer CM; Sowa JP; Möllmann D; Fingas C; Dechȇne A; Sitek B; Eisenacher M; Canbay A; Ahrens M; Baba HA
Virchows Arch; 2017 May; 470(5):537-543. PubMed ID: 28357490
[TBL] [Abstract][Full Text] [Related]
5. Identification of TPD52 and DNAJB1 as two novel bile biomarkers for cholangiocarcinoma by iTRAQ‑based quantitative proteomics analysis.
Ren H; Luo M; Chen J; Zhou Y; Li X; Zhan Y; Shen D; Chen B
Oncol Rep; 2019 Dec; 42(6):2622-2634. PubMed ID: 31661142
[TBL] [Abstract][Full Text] [Related]
6. Novel Biomarker Panels Discriminating between Pancreatic Ductal Adenocarcinoma and Extrahepatic Bile Duct Carcinoma.
Noh BJ; Choi GM; Jang HJ; Ma CH; Oh HS; Kim M; Eom DW
Ann Clin Lab Sci; 2022 Mar; 52(2):323-331. PubMed ID: 35414511
[TBL] [Abstract][Full Text] [Related]
7. Different Clinical Characteristics Between Distal Cholangiocarcinoma and Pancreatic Head Carcinoma With Biliary Obstruction.
Yokoyama Y; Ebata T; Igami T; Sugawara G; Mizuno T; Yamaguchi J; Nagino M
Pancreas; 2017; 46(10):1322-1326. PubMed ID: 28984790
[TBL] [Abstract][Full Text] [Related]
8. Mass spectrometry-based proteomic analysis of formalin-fixed paraffin-embedded extrahepatic cholangiocarcinoma.
Maeda S; Morikawa T; Takadate T; Suzuki T; Minowa T; Hanagata N; Onogawa T; Motoi F; Nishimura T; Unno M
J Hepatobiliary Pancreat Sci; 2015 Sep; 22(9):683-91. PubMed ID: 25917007
[TBL] [Abstract][Full Text] [Related]
9. Identification of novel biomarker candidates for the immunohistochemical diagnosis of cholangiocellular carcinoma.
Padden J; Megger DA; Bracht T; Reis H; Ahrens M; Kohl M; Eisenacher M; Schlaak JF; Canbay AE; Weber F; Hoffmann AC; Kuhlmann K; Meyer HE; Baba HA; Sitek B
Mol Cell Proteomics; 2014 Oct; 13(10):2661-72. PubMed ID: 25034945
[TBL] [Abstract][Full Text] [Related]
10. Expression of integrin ανβ6 differentiates perihilar cholangiocarcinoma (PHC) from benign disease mimicking PHC.
Franken LC; Vuijk FA; Soer EC; Roos E; Erdmann JI; Hooijer GKJ; Vahrmeijer AL; Gambhir SS; van Gulik TM; Sarasqueta AF; Verheij J; Swijnenburg RJ
Eur J Surg Oncol; 2021 Mar; 47(3 Pt B):628-634. PubMed ID: 33069505
[TBL] [Abstract][Full Text] [Related]
11. Differential LC-MS-based proteomics of surgical human cholangiocarcinoma tissues.
Kawase H; Fujii K; Miyamoto M; Kubota KC; Hirano S; Kondo S; Inagaki F
J Proteome Res; 2009 Aug; 8(8):4092-103. PubMed ID: 19569727
[TBL] [Abstract][Full Text] [Related]
12. The novel monoclonal antibody HPC2 and N-cadherin distinguish pancreatic ductal adenocarcinoma from cholangiocarcinoma.
Hooper JE; Morgan TK; Grompe M; Sheppard BC; Troxell ML; Corless CL; Streeter PR
Hum Pathol; 2012 Oct; 43(10):1583-9. PubMed ID: 22406361
[TBL] [Abstract][Full Text] [Related]
13. Combined Expression of Plasma Thrombospondin-2 and CA19-9 for Diagnosis of Pancreatic Cancer and Distal Cholangiocarcinoma: A Proteome Approach.
Le Large TYS; Meijer LL; Paleckyte R; Boyd LNC; Kok B; Wurdinger T; Schelfhorst T; Piersma SR; Pham TV; van Grieken NCT; Zonderhuis BM; Daams F; van Laarhoven HWM; Bijlsma MF; Jimenez CR; Giovannetti E; Kazemier G
Oncologist; 2020 Apr; 25(4):e634-e643. PubMed ID: 31943574
[TBL] [Abstract][Full Text] [Related]
14. An immunohistochemical panel of insulin-like growth factor II mRNA-binding protein 3 (IMP3), enhancer of zeste homolog 2 (EZH2), and p53 is useful for a diagnosis in bile duct biopsy.
Sasaki M; Sato Y
Virchows Arch; 2021 Oct; 479(4):697-703. PubMed ID: 34115196
[TBL] [Abstract][Full Text] [Related]
15. Novel immunohistochemical markers differentiate intrahepatic cholangiocarcinoma from benign bile duct lesions.
Bertram S; Padden J; Kälsch J; Ahrens M; Pott L; Canbay A; Weber F; Fingas C; Hoffmann AC; Vietor A; Schlaak JF; Eisenacher M; Reis H; Sitek B; Baba HA
J Clin Pathol; 2016 Jul; 69(7):619-26. PubMed ID: 26729014
[TBL] [Abstract][Full Text] [Related]
16. The search for novel diagnostic and prognostic biomarkers in cholangiocarcinoma.
Macias RIR; Banales JM; Sangro B; Muntané J; Avila MA; Lozano E; Perugorria MJ; Padillo FJ; Bujanda L; Marin JJG
Biochim Biophys Acta Mol Basis Dis; 2018 Apr; 1864(4 Pt B):1468-1477. PubMed ID: 28782657
[TBL] [Abstract][Full Text] [Related]
17. Clinical Utility of Bile Duct Axis Deviation for Differential Diagnosis Between Pancreatic Head Cancer and Bile Duct Cancer.
Shirakawa T; Tomimaru Y; Hayashi S; Noguchi K; Nishida T; Dono K
Am Surg; 2021 Apr; 87(4):664-669. PubMed ID: 33153309
[TBL] [Abstract][Full Text] [Related]
18. Cancer biomarker discovery for cholangiocarcinoma: the high-throughput approaches.
Silsirivanit A; Sawanyawisuth K; Riggins GJ; Wongkham C
J Hepatobiliary Pancreat Sci; 2014 Jun; 21(6):388-96. PubMed ID: 24616382
[TBL] [Abstract][Full Text] [Related]
19. A prospective proteomic-based study for identifying potential biomarkers for the diagnosis of cholangiocarcinoma.
Shi Y; Deng X; Zhan Q; Shen B; Jin X; Zhu Z; Chen H; Li H; Peng C
J Gastrointest Surg; 2013 Sep; 17(9):1584-91. PubMed ID: 23868055
[TBL] [Abstract][Full Text] [Related]
20. Proteomic profiling of cholangiocarcinoma: diagnostic potential of SELDI-TOF MS in malignant bile duct stricture.
Scarlett CJ; Saxby AJ; Nielsen A; Bell C; Samra JS; Hugh T; Baxter RC; Smith RC
Hepatology; 2006 Sep; 44(3):658-66. PubMed ID: 16941699
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
